Chasing down the triple-negative myeloproliferative neoplasms: Implications for molecular diagnostics

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Classical myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, and primary myelofibrosis are often driven by mutations in JAK2, CALR, or MPL genes.
• A subset of MPN patients, termed 'triple-negative', lack these common mutations, necessitating further investigation into their genetic drivers.

Purpose of the Study:

• To identify novel driver mutations in triple-negative MPN patients.
• To evaluate the effectiveness of current molecular diagnostic approaches for detecting these mutations.
• To inform the development of improved diagnostic algorithms for MPN.

Main Methods:

• Whole or targeted exome sequencing was employed to analyze the mutational status of triple-negative MPN patients.
• Identification and characterization of novel mutations in alternative exons of JAK2 and MPL genes.

Main Results:

• Numerous novel mutations were identified in alternative exons of JAK2 and MPL genes in triple-negative MPN.
• The majority of these newly discovered mutations lead to functional activation of the respective genes.
• Current diagnostic methods may have insufficient coverage to detect these alternative exon mutations.

Conclusions:

• The findings highlight the importance of investigating alternative exons in JAK2 and MPL for a comprehensive molecular diagnosis of MPN.
• Targeted exon sequencing should be considered for routine diagnostic practice to improve MPN detection rates.
• The molecular diagnostic algorithm for MPN requires continuous updates to incorporate these new findings.